참고문헌
- Alimujiang S, Zhang T, Han ZG, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9. https://doi.org/10.7314/APJCP.2013.14.4.2413
- Booth CM, Eisenhauer EA (2012). Progression-Free Survival: Meaningful or Simply Measurable? J Clin Oncol, 30, 1030-3. https://doi.org/10.1200/JCO.2011.38.7571
- Bowater RJ, Bridge LJ, Lilford RJ (2008). The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. Cancer Lett, 262, 48-53. https://doi.org/10.1016/j.canlet.2007.11.032
- Broglio KR, Berry DA (2009). Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst, 101, 1642-9. https://doi.org/10.1093/jnci/djp369
- Burzykowski T, Molenberghs G, Buyse M, et al (2001). Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C Appl Stat, 50, 405-22. https://doi.org/10.1111/1467-9876.00244
- Buyse M, Sargent DJ, Grothey A, et al (2010). Biomarkers and surrogate end points[mdash]the challenge of statistical validation. Nat Rev Clin Oncol, 7, 309-17. https://doi.org/10.1038/nrclinonc.2010.43
- Cheema PK, Burkes RL (2013). Overall survival should be the primary endpoint in clinical trials for advanced non-smallcell lung cancer. Curr Oncol, 20, 150-60.
- Fleischer F, Gaschler-Markefski B, Bluhmki E (2009). A statistical model for the dependence between progressionfree survival and overall survival. Stat Med, 28, 2669-86. https://doi.org/10.1002/sim.3637
- Fu H, Wang Y, Liu J, et al (2013). Joint modeling of progressionfree survival and overall survival by a Bayesian normal induced copula estimation model. Stat Med, 32, 240-54. https://doi.org/10.1002/sim.5487
- Giessen C, Laubender RP, Ankerst DP, et al (2013). Progressionfree survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res, 19, 225-35. https://doi.org/10.1158/1078-0432.CCR-12-1515
- Hall P, Martin MA (1989). A note on the accuracy of bootstrap percentile method confidence intervals for a quantile. Stat Probabil Lett, 8, 197-200. https://doi.org/10.1016/0167-7152(89)90121-1
- Han K, Ren M, Wick W, et al (2014). Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol, 16, 696-706. https://doi.org/10.1093/neuonc/not236
- Hayashi H, Okamoto I, Morita S, et al (2012). Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol, 23, 1537-41. https://doi.org/10.1093/annonc/mdr487
- Hayashi H, Okamoto I, Taguri M, et al (2013). Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer, 14, 261-6. https://doi.org/10.1016/j.cllc.2012.09.006
- Kawakami H, Okamoto I, Hayashi H, et al (2013). Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur J Cancer, 49, 3003-9. https://doi.org/10.1016/j.ejca.2013.05.022
- Lima JPdSN, Santos LVd, Sasse EC, et al (2009). Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis. Eur J Cancer, 45, 601-7. https://doi.org/10.1016/j.ejca.2008.11.006
- Michael JR, Schucany WR (2002). The mixture approach for simulating bivariate distributions with specified correlations. Am Stat, 56, 48-54. https://doi.org/10.1198/000313002753631367
- Mok TSK (2011). Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol, 8, 661-8. https://doi.org/10.1038/nrclinonc.2011.126
- Paoletti X, Oba K, Bang YJ, et al (2013). Progression-free survival as a surrogate for overall survival in advanced/ recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst, 105, 1667-70. https://doi.org/10.1093/jnci/djt269
- Petrelli F, Barni S (2013). Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies. Clin Genitourin Cancer, 11, 385-9. https://doi.org/10.1016/j.clgc.2013.07.012
- Saad ED, Katz A, Buyse M (2010a). Overall survival and postprogression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol, 28, 1958-62. https://doi.org/10.1200/JCO.2009.25.5414
- Saad ED, Katz A, Hoff PM, et al (2010b). Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol, 21, 7-12. https://doi.org/10.1093/annonc/mdp523
- Shi Q, Renfro LA, Bot BM, et al (2011). Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Comput Stat Data An, 55, 2748-57. https://doi.org/10.1016/j.csda.2011.03.014
- Shitara K, Matsuo K, Muro K, et al (2013). Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol, 139, 1383-9. https://doi.org/10.1007/s00432-013-1452-y
- Soria JC, Massard C, Le Chevalier T (2010). Should progressionfree survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol, 21, 2324-32. https://doi.org/10.1093/annonc/mdq204
- Sridhara R, Johnson JR, Justice R, et al (2010). Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst, 102, 230-43. https://doi.org/10.1093/jnci/djp515
- Sundar S, Wu J, Hillaby K, et al (2012). A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol, 125, 493-9. https://doi.org/10.1016/j.ygyno.2011.12.420
- Team RC (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
피인용 문헌
- Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund vol.28, pp.8, 2017, https://doi.org/10.1093/annonc/mdx110
- Clinical significance of post-progression survival in lung cancer vol.8, pp.5, 2017, https://doi.org/10.1111/1759-7714.12463
- Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs vol.7, pp.1, 2019, https://doi.org/10.1080/20016689.2018.1562861